PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Werbeagentur & PR-Agentur co-operate

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Drug Safety - First 'Type A' Accreditation for Independent API Inspections Awarded - As the first API auditor in Europe, blue inspection body GmbH has been accredited to carry out inspections of active pharmaceutical ingredient manufacturers and has been awarded the highest independence rating, type
Drug Safety - First 'Type A' Accreditation for Independent API Inspections Awarded

 

NewswireToday - /newswire/ - Muenster, North Rhine-Westfalia, Germany, 2008/06/10 - As the first API auditor in Europe, blue inspection body GmbH has been accredited to carry out inspections of active pharmaceutical ingredient manufacturers and has been awarded the highest independence rating, type "A" - Blue-Inspection.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The blue inspection body GmbH is the first inspection body for active pharmaceutical ingredients (API) in the European Union to be accredited with the highest level of independence, type A. The audit service provider operates worldwide on behalf of pharmaceutical companies to check whether API suppliers meet the requirements of Good Manufacturing Practice. Audits are considered an important means of improving the safety of medicinal products. Since 2006 they have been required for active pharmaceutical ingredients manufactured in other countries to be allowed to undergo further processing in Europe. It is estimated that almost 80% of all starting materials and excipients for medicinal products in the EU and the USA come from third countries.

blue inspection has been accredited by the DAP German Accreditation System for Testing in accordance with the international standard ISO/IEC 17020. The type A accreditation it has been awarded certifies that the company is a qualified and competent auditor – and that it is independent from the medicinal product manufacturer in Europe as well as from the API supplier that is to be inspected in, for example, India or China.

The importance of plant inspections for the safety of medicinal products is illustrated by the heparin scare in early 2008: at that time a Chinese active pharmaceutical ingredient supplier had supplied contaminated batches of heparin to medicinal product manufacturers worldwide. The result was more than 80 deaths in the USA alone. During investigations it emerged that the US medicinal products agency, the FDA, had not inspected the company as required because of a staff shortage. In Europe, the manufacturers of medicinal products are directly responsible for inspections of suppliers. For these they use, among others, specialized audit service providers such as blue inspection body GmbH.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Werbeagentur & PR-Agentur co-operate

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Drug Safety - First 'Type A' Accreditation for Independent API Inspections Awarded

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dr. Stefan Kettelhoit - Blue-Inspection.com 
+49 251 625620-40 stefan.kettelhoit[.]blue-inspection.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Werbeagentur & PR-Agentur co-operate securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Werbeagentur & PR-Agentur co-operate / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)